CN Patent

CN117624132B — 一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法

Assigned to SHANGHAI XIANGHUI MEDICAL TECHNOLOGY CO LTD · Expires 2026-04-21 · 0y expired

What this patent protects

本发明属药物化学合成技术领域，具体为一种CSF‑1R激酶抑制剂Vimseltinib(DCC‑3014)的制备方法。本发明合成方法反应步骤为：由原料6‑卤代‑2‑甲基吡啶‑3‑醇(1)与硼酸或者硼酸酯类化合物(5)经过suzuki偶联反应得到关键中间体化合物2，再与2,4‑二卤代吡啶(6)在碱性条件下反应得到化合物3，最后再与硼酸或者硼酸酯类化合物(7a‑7b)反应得到目标化合物Vimseltinib(DCC‑3014)(4)

USPTO Abstract

本发明属药物化学合成技术领域，具体为一种CSF‑1R激酶抑制剂Vimseltinib(DCC‑3014)的制备方法。本发明合成方法反应步骤为：由原料6‑卤代‑2‑甲基吡啶‑3‑醇(1)与硼酸或者硼酸酯类化合物(5)经过suzuki偶联反应得到关键中间体化合物2，再与2,4‑二卤代吡啶(6)在碱性条件下反应得到化合物3，最后再与硼酸或者硼酸酯类化合物(7a‑7b)反应得到目标化合物Vimseltinib(DCC‑3014)(4)

Drugs covered by this patent

Patent Metadata

Patent number
CN117624132B
Jurisdiction
CN
Classification
—
Expires
2026-04-21
Drug substance claim
No
Drug product claim
No
Assignee
SHANGHAI XIANGHUI MEDICAL TECHNOLOGY CO LTD
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.